Tekmira Pharmaceuticals Corporation Announces Presentation of Data Using SNALP RNAi Delivery Technology

VANCOUVER, BRITISH COLUMBIA--(Marketwire - October 22, 2008) - Tekmira Pharmaceuticals Corporation (TSX: TKM) announced today that studies conducted by Tekmira and Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen Pharmaceutica, N.V. (J&JPRD), have shown that novel small interfering RNA (siRNA) molecules enabled by Tekmira's proprietary SNALP technology significantly reduce fat storage in the liver.